NCT01563679

Brief Summary

This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies. Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 12, 2012

Completed
15 days until next milestone

First Posted

Study publicly available on registry

March 27, 2012

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2014

Completed
Last Updated

May 28, 2014

Status Verified

May 1, 2014

Enrollment Period

1.9 years

First QC Date

March 12, 2012

Last Update Submit

May 23, 2014

Conditions

Cancer

Keywords

cancerlocoregional therapiesRFACryoablationMicrowave ablationchemical ablationIrreversible electroporation

Outcome Measures

Primary Outcomes (1)

  • Effect of percutaneous and transarterial treatments for cancer in quality of life

    Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.

    1 year

Secondary Outcomes (1)

  • response rate to percutaneous and transarterial treatment for cancer

    1 month, 3 months, 6 months, 1 year.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who undergo ablative therapy procedures, in the Interventional Radiology department as part of a clinical treatment for cancer.

You may qualify if:

  • yrs of age
  • Cancer diagnosis
  • Candidate for Locoregional therapy
  • Willingness to sign informed consent

You may not qualify if:

  • Unable to sign informed consent
  • Patients not eligible for locoregional therapies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emory University Hospital

Altanta, Georgia, 30322, United States

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Hyun S Kim, MD

    Emory University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Interventional Radiology and Image-guided Medicine

Study Record Dates

First Submitted

March 12, 2012

First Posted

March 27, 2012

Study Start

February 1, 2012

Primary Completion

January 1, 2014

Study Completion

January 1, 2014

Last Updated

May 28, 2014

Record last verified: 2014-05

Locations

US(1)